Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SAN DIEGO, June 10, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (“Apricus Bio” or the “Company”) (Nasdaq:APRI) (http://www.apricusbio.com), today announced that its marketing application for Vitaros®, indicated for the treatment of patients with erectile dysfunction (“ED”), has been approved through the European Decentralized Procedure (“DCP”).
Help employers find you! Check out all the jobs and post your resume.
